Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)

ADC ID	DRG0IVHBY
ADC Name	US12144865B2 26e
Synonyms	US12144865B2 26e Click to Show/Hide
Organization	BAYER PHARMA AKTIENGESELLSCHAFT
Drug Status	Investigative
Drug-to-Antibody Ratio	2.9
Structure
Antibody Name	Trastuzumab	Antibody Info
Antigen Name	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	Antigen Info
Payload Name	Undisclosed
Therapeutic Target	Stimulator of interferon genes protein (STING1)	Target Info
Linker Name	Undisclosed
Conjugate Type	Random conjugation through reduced inter-chain cysteines.

General Information of The Activity Data Related to This ADC

Revealed Based on the Cell Line Data

Click To Hide/Show 1 Activity Data Related to This Level

Standard Type	Value	Units	Cell Line	Disease Model
Half Maximal inhibitory Concentration (IC50)Human PBMC	0.051	nM	CVCL_5310	Breast inflammatory carcinoma

Full List of Activity Data of This Antibody-drug Conjugate

Revealed Based on the Cell Line Data

Click To Hide/Show 1 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (IC50)Human PBMC	0.051 nM	Positive HER2 expression (HER2+++/++)
Method Description	Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model	Breast inflammatory carcinoma	KPL4 cells		CVCL_5310

References

Ref 1	Antibody drug conjugates with enzymatically cleavable groups